Dr. Reddy's Laboratories Launches Sevelamer Carbonate for Oral Suspension in the US Market
28 December 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NYSE: RDY) has launched Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, in the US market following approved by the US Food and Drug Administration (USFDA), the company said.

The Renvela brand and generic had US sales of approximately USD101 m MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy's Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90.

Renvela is a trademark of French drugmaker Sanofi.

Dr. Reddy's Laboratories is an integrated pharmaceutical company, whose major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

The company operates in markets across the globe. Our major markets include USA, India, Russia and CIS countries, and Europe.